Opinion|Videos|February 2, 2024

Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

Author(s)Gregory W. Roloff, MD, Jae Park, MD, Bijal D. Shah, MD

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Episodes in this series

EP. 1 Faculty Introductions

EP. 1 Faculty Introductions

EP. 2 Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

EP. 2 Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

EP. 3 Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

EP. 3 Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

EP. 4 Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial

EP. 5 Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

EP. 5 Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

EP. 6 Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

EP. 6 Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

EP. 7 Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

EP. 7 Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

EP. 8 Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

EP. 8 Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

$EP. 9 Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL$

EP. 9 Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

EP. 10 Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

EP. 10 Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

FDA

October 26th, 2026

FDA Grants Breakthrough Therapy Designation to Enzomenib in R/R KMT2A-Rearranged Acute Leukemia

The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

October 26th, 2026

Five Under 5: Top Oncology Videos for the Week of 10/18

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

October 24th, 2026

The OncFive: Top Oncology Articles for the Week of 10/18

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

Trending on OncLive

FDA Receives BLA for Etentamig in R/R Multiple Myeloma

Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos

T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer

Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide

Basser Center for BRCA Awards 2026 Global Prize to Judy Garber